| Product NDC: | 51079-998 |
| Proprietary Name: | Tizanidine |
| Non Proprietary Name: | tizanidine |
| Active Ingredient(s): | 4 mg/1 & nbsp; tizanidine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 51079-998 |
| Labeler Name: | UDL Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA076354 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110128 |
| Package NDC: | 51079-998-20 |
| Package Description: | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-998-20) > 1 TABLET in 1 BLISTER PACK (51079-998-01) |
| NDC Code | 51079-998-20 |
| Proprietary Name | Tizanidine |
| Package Description | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-998-20) > 1 TABLET in 1 BLISTER PACK (51079-998-01) |
| Product NDC | 51079-998 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | tizanidine |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110128 |
| Marketing Category Name | ANDA |
| Labeler Name | UDL Laboratories, Inc. |
| Substance Name | TIZANIDINE HYDROCHLORIDE |
| Strength Number | 4 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha2-Agonists [MoA],Central alpha-2 Adrenergic Agonist [EPC] |